Page last updated: 2024-12-06

cysteic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cysteic acid is an amino acid formed by the oxidation of cysteine. It is a sulfated amino acid that plays a role in various biological processes, including detoxification and antioxidant activity. Cysteic acid is found in various tissues and organs, including the brain, liver, and kidneys. It is formed through the oxidation of cysteine by various enzymes, including cysteine dioxygenase and sulfite oxidase. The formation of cysteic acid can occur both enzymatically and non-enzymatically. Cysteic acid has been implicated in various neurological disorders, including Alzheimer's disease and Parkinson's disease. It is believed to be involved in the formation of amyloid plaques, which are characteristic of Alzheimer's disease. Cysteic acid also exhibits neurotoxic effects, potentially contributing to neuronal damage in neurodegenerative diseases. Additionally, cysteic acid is a potent activator of NMDA receptors, which are involved in synaptic plasticity and learning. Cysteic acid is also found in food products, including dairy products, eggs, and meat. It is used as a food additive to improve flavor and texture. The synthesis of cysteic acid can be achieved through various methods, including oxidation of cysteine with hydrogen peroxide or potassium permanganate. Cysteic acid is a valuable research tool for studying various biological processes, including oxidative stress, neurotoxicity, and the function of NMDA receptors. The study of cysteic acid can help elucidate the underlying mechanisms of various diseases and contribute to the development of new therapeutic strategies.'

Cysteic Acid: Beta-Sulfoalanine. An amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate. It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cysteic acid : An amino sulfonic acid that is the sulfonic acid analogue of cysteine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID25701
CHEMBL ID1171434
CHEBI ID21260
SCHEMBL ID44030
MeSH IDM0005538

Synonyms (54)

Synonym
STL301905
cysteinic acid
nsc-254030
cepteic acid
cipteic acid
cysteric acid
cysteic acid
nsc254030
inchi=1/c3h7no5s/c4-2(3(5)6)1-10(7,8)9/h2h,1,4h2,(h,5,6)(h,7,8,9
3-sulfoalanine
13100-82-8
dl-cysteic acid
C-9550
3024-83-7
2-amino-3-sulfopropanoic acid
FT-0655399
CHEMBL1171434
chebi:21260 ,
cysteate
beta-sulfoalanine
alanine, 3-sulfo-
unii-a3ogp4c37w
a3ogp4c37w ,
A820275
2-azanyl-3-sulfo-propanoic acid
bdbm85473
l-cysteic acid, 8
AKOS005174455
nsc 254030
FT-0683826
FT-0627746
cysteinesulfonate
cysteic acid, dl-
cysteic acid [mi]
SCHEMBL44030
3-sulfoalanine, (l)-
XVOYSCVBGLVSOL-UHFFFAOYSA-N
mfcd00007524
mfcd00065088
3-sulfoalanine (h-dl-cys(o3h)-oh)
cipteate
cepteate
cysterate
cysteinsaure
2-amino-3-sulfopro-panoic acid
DTXSID40862048
Q2823250
2-amino-3-sulfopropionate
BBL100099
chempacific41266
LS-04435
Z1198149799
EN300-717791
SY113770

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with cysteic acid, 50 mg/kg, IP, prolonged ethanol-produced narcosis."( Taurine, analogues and ethanol elicited responses.
Messiha, FS,
)
0.45

Toxicity

ExcerptReferenceRelevance
" Large (19-fold) increases in cortical cysteine sulphinate concentration were noted after injection of a toxic dose of cysteine."( Cysteine sulphinate and cysteate: mediators of cysteine toxicity in the neonatal rat brain?
Hagberg, H; Lehmann, A; Orwar, O; Sandberg, M, 1993
)
0.29
" Both compounds were innocuous under normal conditions but became toxic in energy-deprived (lack of oxygen or glucose) slices."( The neurotoxicity of sulfur-containing amino acids in energy-deprived rat hippocampal slices.
Heine, MF; Rigor, BM; Schurr, A; West, CA, 1993
)
0.29

Bioavailability

ExcerptReferenceRelevance
" A virtual fragment screen was undertaken of the enzyme to discover starting points for the development of inhibitors which are likely to have appropriate physicochemical properties for an orally bioavailable compound."( Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
Alibu, VP; Barrett, MP; Brenk, R; Campbell, G; Gilbert, IH; Ruda, GF, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
animal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
alanine derivativeAn amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of alanine by a heteroatom. The definition normally excludes peptides containing alanine residues.
amino sulfonic acidAn organosulfonic acid containing one or more amino groups.
carboxyalkanesulfonic acid
cysteine derivativeAn amino acid derivative resulting from reaction of cysteine at the amino group, carboxy group, or thiol group, or from the replacement of any hydrogen of cysteine by a heteroatom. The definition normally excludes peptides containing cysteine residues.
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Taurine and Hypotaurine Metabolism59
Taurine and Hypotaurine Biosynthesis15
Biochemical pathways: part I0466

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
proteolysisN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
protein deglycosylationN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
N4-(beta-N-acetylglucosaminyl)-L-asparaginase activityN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
protein bindingN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
peptidase activityN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
extracellular spaceN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
lysosomeN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
endoplasmic reticulumN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
azurophil granule lumenN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
cytoplasmN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
lysosomeN(4)-(beta-N-acetylglucosaminyl)-L-asparaginaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1799666Inhibition Assay from Article 10.1080/14756360109162375: \\Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors.\\2001Journal of enzyme inhibition, , Volume: 16, Issue:3
Glycosylasparaginase inhibition studies: competitive inhibitors, transition state mimics, noncompetitive inhibitors.
AID492274Inhibition of Trypanosoma brucei 6PGDH expressed in Escherichia coli at 200 uM by spectroscopy2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (225)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990102 (45.33)18.7374
1990's51 (22.67)18.2507
2000's34 (15.11)29.6817
2010's29 (12.89)24.3611
2020's9 (4.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.31 (24.57)
Research Supply Index5.46 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index70.08 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.43%)5.53%
Reviews4 (1.72%)6.00%
Case Studies2 (0.86%)4.05%
Observational0 (0.00%)0.25%
Other225 (96.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]